Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $44.06

Shares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have received an average recommendation of "Moderate Buy" from the twenty-two research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $44.0556.

A number of research firms have recently weighed in on EXEL. UBS Group set a $38.00 price target on Exelixis and gave the stock a "neutral" rating in a research note on Wednesday, July 30th. Jefferies Financial Group set a $50.00 target price on Exelixis and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Guggenheim restated a "buy" rating and issued a $45.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. Bank of America raised their target price on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Finally, JMP Securities restated a "market outperform" rating and issued a $50.00 target price on shares of Exelixis in a research note on Tuesday, July 29th.

Exelixis Stock Up 2.1%

Shares of EXEL traded up $0.7780 during mid-day trading on Monday, hitting $38.6380. The stock had a trading volume of 930,699 shares, compared to its average volume of 3,044,084. The company has a market cap of $10.40 billion, a PE ratio of 18.57, a PEG ratio of 0.77 and a beta of 0.29. Exelixis has a fifty-two week low of $25.12 and a fifty-two week high of $49.62. The company's fifty day simple moving average is $41.68 and its two-hundred day simple moving average is $39.21.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Equities analysts expect that Exelixis will post 2.04 earnings per share for the current year.

Insider Activity

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total transaction of $324,683.15. Following the completion of the transaction, the director owned 358,882 shares of the company's stock, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sue Gail Eckhardt sold 18,838 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $42.74, for a total transaction of $805,136.12. Following the completion of the sale, the director owned 21,380 shares in the company, valued at $913,781.20. This represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.82% of the company's stock.

Institutional Investors Weigh In On Exelixis

Hedge funds have recently modified their holdings of the business. Envestnet Asset Management Inc. boosted its holdings in shares of Exelixis by 17.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 200,228 shares of the biotechnology company's stock valued at $6,668,000 after purchasing an additional 29,892 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Exelixis during the 4th quarter valued at about $17,046,000. Sterling Capital Management LLC raised its position in shares of Exelixis by 7.8% during the 4th quarter. Sterling Capital Management LLC now owns 6,627 shares of the biotechnology company's stock valued at $221,000 after buying an additional 477 shares in the last quarter. Barclays PLC raised its position in shares of Exelixis by 8.9% during the 4th quarter. Barclays PLC now owns 348,009 shares of the biotechnology company's stock valued at $11,587,000 after buying an additional 28,420 shares in the last quarter. Finally, Mariner LLC raised its position in shares of Exelixis by 13.1% during the 4th quarter. Mariner LLC now owns 20,373 shares of the biotechnology company's stock valued at $678,000 after buying an additional 2,355 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.